Indaptus Therapeutics, Inc. current report, 13 July 2021

Form 8-K Summary

Business Context and Reporting Period

Intec Parent, Inc. filed a Current Report on Form 8-K under Item 8.01, Other Events. The report concerns litigation related to the proposed merger of Intec Pharma Ltd. with Decoy Biosystems, Inc. The earliest reported event occurred on July 13, 2021; the filing was signed July 16, 2021. The filing identifies Intec Parent, Inc. as the registrant; the request metadata identifies the company as Indaptus Therapeutics, Inc.

Financial Metrics and Liquidity

The filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other operating financial metrics.

Material Changes Versus the Prior Comparable Period

  • No period-over-period financial information is presented.
  • Four shareholder-related lawsuits were voluntarily dismissed between May 13 and July 13, 2021.
  • On July 13, 2021, the defendants agreed that Intec Israel would pay plaintiffs’ counsel $225,000.

Guidance, Outlook, Risks, Contingencies, and Unusual Items

The actions alleged that Intec Israel’s directors breached fiduciary duties in approving the merger and that the proxy statement/prospectus omitted or misrepresented material information. Intec Israel made supplemental proxy disclosures on May 12, 2021, through Amendment No. 1 to the Registration Statement. The litigation resolution and $225,000 payment are unusual legal-related items. The filing does not state the accounting treatment, payment date, insurance recovery, or any remaining litigation contingency.

Key Facts for Investors to Verify

  • Confirm the final status and terms of the merger involving Intec Israel and Decoy Biosystems.
  • Verify payment of the $225,000 plaintiffs’ counsel fee and its impact on the company’s financial statements.
  • Review the May 12, 2021 supplemental proxy disclosures and the related Registration Statement.
  • Determine whether any related claims, appeals, indemnification obligations, or other litigation remain outstanding.
  • Reconcile the registrant’s historical name and corporate identity with the company identified in the request metadata.